Recifercept is the name Pfizer as selected for the orphan drug for achondroplasia. Pfizer acquired Therachon in May 2019, and with that, TA-46, the new molecule being developed as a potential treatment for achondroplasia.

Ascendis Pharma is developing the TransCon CNP program at a swift pace and moving forward with phase 2 ACcomplisH Trial to evaluate the safety and efficacy of TransCon CNP in children with achondroplasia.  

It has been recently published, in August 2019, the "Quality of life of children with achondroplasia and their parents - a German cross-sectional study" at the Orphanet Journal of Rare Diseases. This study investigated the quality of life of children with achondroplasia from children and parent’s perspective and also the parental quality of life.

BioMarin investigational medicine for achondroplasia, BMN-111, known as vosoritide, is currently in phase 3 of the medicine development process and this is an update provided by the company in late July 2019.

The PROPEL trial is the Prospective Study in Children with Achondroplasia now recruiting children from 2,5 to 10 years old.

Dr. Ravi Savarirayan and his team published a paper with results from Biomarin's Vosoritide phase 2 dose-finding and extension study for children with achondroplasia aged 5-14 years, showing an increase in annualized growth velocity.